Charts

MEDFORD, N.Y., March 21, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA. Fellow Chembio Stockholders, As previously disclosed, Chembio Diagnostics, Inc. (“Chembio” or the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”), dated as of January 31, 2023, with Biosynex SA,

MEDFORD, N.Y., March 15, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA. March 15, 2023 Fellow Chembio Stockholders, As previously disclosed, Chembio Diagnostics, Inc. (“Chembio” or the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”), dated as of January 31, 2023, wit

STRASBOURG, France, March 15, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced that Project Merci Merger Sub, Inc. (“Purchaser”), a Nevada corporation and its wholly-owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock (the “Shares”) of Chembio Diagnostics, Inc. (Nasd

MEDFORD, N.Y., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced receipt of a Clinical Laboratory Improvement Amendments (CLIA) waiver from the U.S. Food and Drug Administration (FDA) for the DPP HIV-Syphilis System. “The DPP HIV-Syphilis System represents an exciting advancement in rapid testing for sexually transmitted infections. We are excited that the 200,000+ CLIA waived po

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Chembio Diagnostics, Inc. (NasdaqCM: CEMI) to Biosynex SA. Under the terms of the proposed transaction, shareholders of Chembio will receive $0.45 in cash for each share of Chembio that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

Gainers Versus Systems Inc. (NASDAQ: VS) surged 270% to $2.26 after the company announced it will partner with Resolve to bring ...

Gainers Bright Green (NASDAQ:BGXX) shares increased by 251.2% to $1.83 during Wednesday's regular session. The current volume of 81.8 ...

Privately heldBiosynex SAhasagreed to acquireChembio Diagnostics Inc(NASDAQ: CEMI) for $0.45 per share ...

Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) stock rose 76.6% to $2.95 during Wednesday's pre-market session. The company's market cap ...

Gainers Motorsport Games Inc. (NASDAQ: MSGM) shares rose 121% to $47.48 in pre-market trading after jumping over 710% on Tuesday. ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's time for another look at the biggest pre-market stock movers worth checking out as we start off trading early on Wednesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Chembio Diagnostics, Inc. (NASDAQ: CEMI) to Biosynex SA for $0.45 per share is fair to Chembio shareholders.

Complementary Technologies, Product Portfolios, and Market Opportunities Expected to Represent Significant Growth Drivers Consolidated Manufacturing, Sales, Marketing, Operations to Provide Synergistic Cost Savings STRASBOURG, France and HAUPPAUGE, N.Y., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, and Chembio Diagnostics, Inc. (“Chembio”) (Nasdaq: CEMI), a leading point-of-care diagnos

Gainers Quotient (NASDAQ:QTNT) stock rose 35.8% to $0.33 during Wednesday's after-market session. This security traded at a volume of ...

Gainers Neptune Wellness Solutions Inc.(NASDAQ: NEPT) shares rose 106.9% to $0.5482 in pre-market trading on heavy ...

Gainers Eargo (NASDAQ:EAR) shares moved upwards by 18.7% to $0.73 during Monday's after-market session. Trading volume for this ...

Gainers Enveric Biosciences (NASDAQ:ENVB) shares increased by 12.0% to $2.98 during Thursday's after-market session. The market value ...

Gainers Lannett (NYSE:LCI) stock moved upwards by 14.5% to $0.71 during Friday's after-market session. The market value of their ...

HAUPPAUGE, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the submission to the U.S. Food and Drug Administration (FDA) for a Clinical Laboratory Improvement Amendments (CLIA) waiver for the DPP HIV-Syphilis System. “We are pleased to communicate that our DPP HIV-Syphilis System has been submitted to FDA for CLIA waiver. Upon receipt of CLIA waiver, we believe this will

Gainers IVERIC bio (NASDAQ:ISEE) stock moved upwards by 22.3% to $21.09 during Friday's pre-market session. The company's market cap ...

HAUPPAUGE, N.Y., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (“Chembio” or the “Company”) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended September 30, 2022. Recent Highlights Achieved third quarter 2022 total revenue of $11.2 million including product revenue of $10.8 million, representing product revenue growth of 16% compared to the prior year periodU.S. product revenue of $4.8 m

Researchers have warned that a dangerous monkeypox variant with a fatality rate as high as 10% is circulating in Central Africa, ...

HAUPPAUGE, N.Y., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the third quarter of 2022 after the close of trading on Thursday, November 3, 2022. The company’s management team will host a corresponding conference call beginning at 4:30 p.m. Eastern Time on November 3, 2022. Investors interested in listening to the conference call ma

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Get ready for one more day of trading this week as we break down the biggest pre-market stock movers for Friday morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

Gainers Corbus Pharmaceuticals (NASDAQ:CRBP) shares rose 24.6% to $0.14 during Thursday's pre-market session. The market value ...

Gainers Vox Royalty Corp. (NASDAQ: VOXR) rose 60.4% to $4.33 in pre-market trading. Vox Royalty’s common shares commenced ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! It's time to start the day with a breakdown of the biggest pre-market stock movers for Tuesday morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

Gainers FingerMotion, Inc. (NASDAQ: FNGR) gained 82.2% to close at $3.37. SAI.TECH Global Corporation (NASDAQ: SAI) gained 43.4% ...

The FDA said it willnow reviewonly a small number of emergency use authorization (EUA) requests for COVID-19 diagnostic ...

The World Health Organization (WHO)warnedthat it struggles to identify and track new Covid variants as governments roll back ...

Gainers Infobird Co., Ltd (NASDAQ: IFBD) rose 70.8% to $3.16 in pre-market trading after 1:5 reverse stock split takes ...

Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 176.5% to close at $31.00 on Thursday after the company announced plans to ...

Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 73.8% to $19.48 after the company announced plans to spin-off ShiftPixy Labs ...

Gainers Asana, Inc. (NYSE: ASAN) rose 24.1% to $23.62 in pre-market trading after the company reported better-than-expected ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! It's time for another overview of the biggest pre-market stock movers as we see what's happening on Thursday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

HAUPPAUGE, N.Y., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced it was awarded a $3.2 million contract from the Centers for Disease Control and Prevention (CDC) for the development and clinical validation of a rapid point-of-care (POC) diagnostic test for syphilis. Chembio will undertake to develop a syphilis test and confirm assay based on its Dual Path Platform (D

Gainers NewAge, Inc. (NASDAQ: NBEV) shares rose 58.3% to $0.1935 in pre-market trading. NewAge shares tumbled around 47% on ...

CNBC reportedthat the federal government is set to suspend its offer of free at-home COVID-19 tests by Friday, September 2, ...

Gainers Homology Medicines (NASDAQ:FIXX) shares rose 11.3% to $3.16 during Monday's pre-market session. The market ...

Gainers NewAge, Inc. (NASDAQ: NBEV) shares rose 19.7% to $0.2432 in pre-market trading. NewAge recently received Nasdaq notice on ...

According to the World Health Organization, health officials arewitnessing early signsthat the new monkeypox case growth ...

Applied DNA Sciences Inc(NASDAQ: APDN) has submitted to the New York State Department of Health (NYSDOH) avalidation ...

Chembio Diagnostics Inc(NASDAQ: CEMI) isevaluating the potentialto develop a monkeypox rapid point-of-care (POC) ...

Gainers Chembio Diagnostics (NASDAQ:CEMI) shares increased by 26.4% to $1.1 during Tuesday's pre-market session. The ...

HAUPPAUGE, N.Y., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced it is evaluating the potential to develop a monkeypox rapid point-of-care (POC) test. Chembio is exploring the technical requirements for test development leveraging its multiple technology platforms, DPP, SURE CHECK, and STAT PAK, along with funding partners and the broader market opportunity. “We are i

Gainers Bonso Electronics International Inc. (NASDAQ: BNSO) shares rose 46% to $6.98 in pre-market trading after jumping around ...

Gainers Assure Holdings Corp. (NASDAQ: IONM) shares jumped 88.8% to $3.9650 after jumping around 104% on ...

Gainers Assure Holdings Corp. (NASDAQ: IONM) shares rose 141.4% to $5.07 in pre-market trading after jumping around 104% on ...

Chembio Diagnostics (NASDAQ:CEMI) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:05 PM. Here's what investors ...

HAUPPAUGE, N.Y., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (“Chembio” or the “Company”) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended June 30, 2022. Recent Highlights Achieved second quarter 2022 total revenue of $9.2 million including product revenue of $8.9 million, representing growth of 42% and 125%, respectively, compared to the prior year period: U.S. product revenue of $3

HAUPPAUGE, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the second quarter of 2022 after the close of trading on Thursday, August 4, 2022. The company’s management team will host a corresponding conference call beginning at 4:30 p.m. Eastern Time on August 4, 2022. Investors interested in listening to the conference call may d

Initiates distribution of SCoV-2 Ag Detect Self-Test to consumers in the United States and expansion of SURE CHECK HIV Self-Test distribution to consumers in Brazil and the United KingdomHAUPPAUGE, N.Y., June 15, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the launch of its direct-to-consumer commercial channel for the third-party SCoV-2 Ag Detect Self-Test in the U.S. mark

HAUPPAUGE, N.Y., May 24, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the election of Leslie Teso-Lichtman to its Board of Directors at Chembio’s 2022 Annual Meeting of Stockholders. “We are excited to have Leslie join the Chembio Board of Directors,” said Richard Eberly, Chembio’s Chief Executive Officer and President. “Her significant experience in corporate financial lead

HAUPPAUGE, N.Y., May 17, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced it has entered into a manufacturing agreement with Reszon Diagnostics International Sdn. Bhd. (Reszon) to produce Chembio’s HIV 1/2 STAT-PAK Assay products in the Chembio Diagnostics Malaysia (CDM) facility. CDM had previously suspended operations in May 2020. This new manufacturing arrangement will levera

HAUPPAUGE, N.Y., May 05, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (“Chembio” or the “Company”) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended March 31, 2022. Recent Highlights Achieved total revenue of $18.8 million including record quarterly product revenue of $18.5 million in the first quarter of 2022, representing growth of 116% and 360%, respectively, compared to the prior year perio

HAUPPAUGE, N.Y., April 21, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the first quarter of 2022 after the close of trading on Thursday, May 5, 2022. The company’s management team will host a corresponding conference call beginning at 4:30 p.m. Eastern Time on May 5, 2022. Investors interested in listening to the conference call may do so b